References
- Chung L, Fiorentino D. Cutaneous vasculitis. Orphanet encyclopedia. March 2005. Available from: http://www.orpha.net/data/patho/GB/uk-cutaneous-vasculitis.pdf [last accessed 11 Dec 2012]
- Su B-A, Shen W-L, Chang S-T, et al. Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: a case report. Oncol Lett 2012;3:1280–2
- Takahashi Y, Ebi N, Yamaguchi O, et al. A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature. Nihon Kokyuki Gakkai Zasshi 2011;49:663–6
- Yuba T, Nagata K, Shiotsu S, et al. Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report. Nihon Kokyuki Gakkai Zasshi 2010;48:81–5
- Boeck S, Wollenberg A, Heinemann V. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Ann Oncol 2007;18:1582–3
- Gutzmer R, Wollenberg A, Ugurel S, et al. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int 2012;109:133–40
- Electronic Medicines Compedium (eMC) Erlotinib. Summary of product characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/16781/SPC/Tarceva+25mg%2c+100mg+and+150mg+Film-Coated+Tablets/#INDICATIONS [last accessed 2 Jul 2012]
- Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843–50
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90
- Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34
- Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006;17:1227–9
- Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 2008;7:144–8
- Garcia-Navarro X, Puig L, Fernández-Figueras MT, et al. Bortezomib-associated cutaneous vasculitis. Br J Dermatol 2007;157:799–801
- Campanati A, Berardi R, Onofri A, et al. A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. Ann Oncol 2012;23:1081–2
- Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009;3:294–9
- Uchimiya H, Higashi Y, Kawai K, Kanekura T. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib. J Dermatol 2010;37:562–4
- Najarian DJ, Packianathan V, Zeitouni NC. Annular leukocytoclastic vasculitis associated with sorafenib administration. J Drugs Dermatol 2010;9:697–8
- Chung NM, Gutierrez M, Turner ML. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 2006;142:1510–11
- Yee KWL, Hymes SR, Heller L, et al. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. Leuk Lymphoma 2006;47:926–9
- Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534–40